Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD): Establishing a Core Outcome Set for Trials in Patients with Glomerular Disease

Simon A. Carter,Liz Lightstone,Daniel Cattran,Arvind Bagga,Sean J. Barbour,Jonathan Barratt,John Boletis,Dawn Caster,Rosanna Coppo,Fernando C. Fervenza,Jürgen Floege,Michelle Hladunewich,Jonathan J. Hogan,A. Richard Kitching,Richard Lafayette,Ana Malvar,Jai Radhakrishnan,Brad H. Rovin,Hong Zhang,Talia Gutman
DOI: https://doi.org/10.1016/j.kint.2019.01.047
IF: 19.6
2019-01-01
Kidney International
Abstract:Glomerular diseases (GDs) impose a substantial burden on patients and health systems, and they are a major cause of end-stage kidney disease (ESKD) worldwide.1 The causes and clinical features of GD are diverse, yet as a group they share many symptoms, treatments, and outcomes (Table 1). Patients with primary and secondary GDs have mortality rates 2.7- and 3.9-fold higher than the general population, respectively, higher rates of cardiovascular events, and they report impaired quality of life.1 Treatment side effects may include diabetes, poor bone health, obesity, infection, reduced fertility, and cancer, and also affect quality of life.
What problem does this paper attempt to address?